title: The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia.
abstract: Approximately 45% of newly diagnosed patients with essential thrombocythaemia (ET) demonstrate subnormal plasma erythropoietin (EPO) concentrations, which constitutes a risk factor for occlusive vascular events. In 58 ET patients, a possible association between polycythaemia rubra vera-1 (PRV-1) overexpression and subnormal plasma EPO was investigated, which was always measured prior to the institution of platelet lowering agents. At the time when PRV-1 expression was measured, 28 of 58 (48%) ET patients had received platelet lowering treatment. PRV-1 expression was measured by quantitative real-time reverse transcription-polymerase chain reaction assay of mRNA extracted from purified peripheral blood buffy coat. The cycle threshold (CT) value of PRV-1 was determined and was divided with the CT value for the housekeeping GAPDH gene transcript. A quotient <0.93 was defined as PRV-1 positive. Of the ET patients 12 of 58 (21%) were PRV-1 positive and 19 of 58 (33%) demonstrated subnormal plasma EPO. In the 58 ET patients there was a significant association between low plasma EPO and PRV-1 positive results (P = 0.001). The 30 ET patients who had not received any platelet lowering treatment showed a significant (P = 0.005) relation between PRV-1 positivity and subnormal plasma EPO. No such relationship was present in the 28 ET patients who had received prior treatment with the above drugs (P = 0.147).
authors.affiliation: Haematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden. peter.l.johansson@vgregion.se
authors.forename: Peter
authors.initials: P
authors.lastname: Johansson
authors.forename: Björn
authors.initials: B
authors.lastname: Andréasson
authors.forename: Soodabeh
authors.initials: S
authors.lastname: Safai-Kutti
authors.forename: Lovisa
authors.initials: L
authors.lastname: Wennström
authors.forename: Lars
authors.initials: L
authors.lastname: Palmqvist
authors.forename: Anne
authors.initials: A
authors.lastname: Ricksten
authors.forename: Göran
authors.initials: G
authors.lastname: Lindstedt
authors.forename: Jack
authors.initials: J
authors.lastname: Kutti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002452:Cell Count; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D058851:GPI-Linked Proteins; D006098:Granulocytes / Q000166:cytology; D006801:Humans; D007519:Isoantigens; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000235:genetics*; D013922:Thrombocytosis / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D015854:Up-Regulation
chemical_list: C407242:CD177 protein, human; D058851:GPI-Linked Proteins; D007519:Isoantigens; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D004921:Erythropoietin